The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that concludes a protracted legal battle within the genetic testing sector, the U.S. Supreme Court declined to hear an appeal by CareDx against its rival Natera. The case centered on a false-advertising lawsuit where CareDx sought $45 million in damages. By rejecting the petition, the Supreme Court left intact a lower court ruling that required specific proof of deception even in cases of deliberately false advertising, a threshold CareDx failed to meet.
This decision strengthens Natera's legal standing in the competitive 'Prospera' testing market, following previous patent disputes with other peers like Guardant Health. Per market data, the resolution of this dispute removes the threat of a significant $45 million payout that had been looming over the company’s financials. Legal experts suggest this ruling sets a high bar for proving damages in unfair competition cases within the biotechnology industry.
Sign in to access this content
Sign InRegarding market performance, NTRA shares remained at key levels as of the close on May 31, 2026, with investors focusing on how the removal of legal overhangs will impact future margins. Looking ahead, the market is awaiting the Core PCE Price Index release on May 28, 2026, which serves as a critical catalyst for broader sentiment in high-growth healthcare stocks.